Kymriah Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kymriah market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historic period can be attributed to the rising prevalence of cancer, increased public-private investments in the healthcare sector, a growing number of leukemia cases, higher investments in research and development for drug discovery, and the expansion of healthcare infrastructure.

The expected growth during the forecast period is driven by an increasing number of clinical trials, rising demand for personalized and targeted therapies, a growing rate of cancer diagnoses, increased investment in biotechnology, and a greater demand for effective treatments. Key trends during the forecast period include technological advancements in personalized medicine, the integration of artificial intelligence (AI) in CAR-T cell therapy, improvements in manufacturing processes, ongoing research to enhance efficacy, and a rising demand for combination therapies.

The increasing prevalence of hematological cancer is expected to drive the growth of the kymriah market in the future. Hematological cancer encompasses cancers affecting the blood, bone marrow, lymph nodes, and lymphatic system. The rise in these cancers is linked to factors such as an aging population, genetic predispositions, immune system disorders, and lifestyle influences. Kymriah is utilized in the treatment of hematological cancers, specifically certain types of leukemia and lymphoma, by leveraging CAR-T cell therapy to target and destroy cancer cells. For example, in September 2024, the Leukemia & Lymphoma Society (LLS), a US-based charitable organization focused on fighting blood cancers worldwide, reported that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every 3 minutes, with an estimated 187,740 diagnoses of these cancers in 2024. Consequently, the rising prevalence of hematological cancers is driving the growth of the kymriah market.

The growing demand for personalized therapies is another major factor fueling the kymriah market's expansion. Personalized therapies are tailored medical treatments designed to align with an individual's genetic, environmental, and lifestyle characteristics, enhancing their effectiveness and minimizing side effects. The rising demand for these therapies can be attributed to advancements in genetic research, improved understanding of diseases at the molecular level, and enhanced diagnostic tools. Kymriah is particularly advantageous for personalized therapies as it uses a patient's immune cells to target and destroy specific cancer cells, offering a highly customized treatment approach. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. As a result, the growing demand for personalized therapies is propelling the growth of the kymriah market.

A key trend in the kymriah market is the focus on advancing CAR-T cell therapies to improve treatment efficacy and expand the eligible patient population for various hematological cancers. CAR-T cell therapies involve genetically modifying a patient's T cells to express chimeric antigen receptors (CAR), enabling them to detect and eliminate cancer cells, particularly in certain leukemias and lymphomas. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Kymriah (tisagenlecleucel) to treat adult patients with relapsed or refractory follicular lymphoma after undergoing two or more lines of systemic therapy. Kymriah has shown durable results, with 86% of patients responding positively and 68% achieving complete remission. Its ability to provide lasting outcomes, particularly in high-risk patients, sets it apart from other treatments. Notably, Kymriah remains the only CAR-T cell therapy approved for both adult and pediatric patients across multiple indications.

The key company operating in the kymriah market is Novartis AG.

North America was the largest region in the kymriah market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kymriah report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kymriah market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kymriah is a CAR-T cell therapy designed to modify a patient's T cells to specifically target and attack cancer cells. It is used to treat certain blood cancers by extracting, engineering, and reinfusing T cells that are programmed to recognize cancer-specific markers. This groundbreaking treatment has shown remarkable efficacy in patients with cancers resistant to conventional therapies, offering a potentially life-saving solution.

The primary types of kymriah formulations include injectable formulations (intravenous) and customized patient-specific formulations. Injectable intravenous formulations deliver medication directly into the vein, ensuring precise, rapid, and controlled treatment, making them suitable for various conditions. Kymriah is indicated for the treatment of B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and other conditions. It is used across diverse patient demographics, including pediatric, adult, and geriatric populations. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Kymriah is utilized by a range of end users, such as hospitals, oncology clinics, hematology treatment centers, and research institutions.

The kymriah market research report is one of a series of new reports that provides kymriah market statistics, including the kymriah industry global market size, regional shares, competitors with the kymriah market share, detailed kymriah market segments, market trends, and opportunities, and any further data you may need to thrive in the kymriah industry. This kymriah market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kymriah market consists of sales of leukapheresis kits, infusion kits, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.